Let's go back again to charts of VIAB.
It will need to find another gear for ticket sales.
Let's see how bad the charts look.
NVDA may be back in the game, but they aren't the star again. At least not yet.
Let's see what the charts say.
Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.
MN looks like it could move higher and rally, but the uneven trading pattern tells me to look for easier set-ups.
Should the early low of the day hold on Friday, these shares will have bottomed at nearly the same price for three sessions in a row. Is that meaningful?
Let's see what the charts look like.
A couple key charts indicate momentum in the company's shares is slowing, which could foreshadow a consolidation phase or a correction.